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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYPatients with an HNF1BS148L/+ mutation (MODY5) typically exhibit pancreatic hypoplasia. However, the molecular mechanisms are
unknown due to inaccessibility of patient material and because mouse models do not fully recapitulate MODY5. Here, we differenti-
ated MODY5 human-induced pluripotent stem cells (hiPSCs) into pancreatic progenitors, and show that the HNF1BS148L/+ mutation
causes a compensatory increase in several pancreatic transcription factors, and surprisingly, a decrease in PAX6 pancreatic gene expres-
sion. The lack of suppression of PDX1, PTF1A, GATA4, and GATA6 indicates that MODY5-mediated pancreatic hypoplasia is mecha-
nistically independent. Overexpression studies demonstrate that a compensatory increase in PDX1 gene expression is due to mutant
HNF1BS148L/+ but not wild-type HNF1B or HNF1A. Furthermore, HNF1B does not appear to directly regulate PAX6 gene expression
necessary for glucose tolerance. Our results demonstrate compensatory mechanisms in the pancreatic transcription factor network
due to mutant HNF1BS148L/+ protein. Thus, patients typically develop MODY5 but not neonatal diabetes despite exhibiting pancreatic
hypoplasia.INTRODUCTION
Maturity-onset diabetes of the young (MODY) is a type of
autosomal dominant monogenic diabetes classically char-
acterized by non-ketotic, non-insulin-dependent diabetes
occurring before the age of 25 years (Teo et al., 2013a).
Many MODY genes are pancreatic developmental tran-
scription factors, with the notable exception of GCK,
CEL, and INS. Although MODY was discovered more than
two decades ago, the molecular mechanisms underlying
transcription factor MODY in humans is still largely un-
clear because mouse models do not fully recapitulate this
disease (Maestro et al., 2007) and the lack of a suitable hu-
man model.
Patients with MODY5 commonly exhibit pancreatic hy-
poplasia due to an autosomal dominant mutation in the
HNF1B gene (Edghill et al., 2006). HNF1B is a member of
the complex pancreatic transcription factor networkwhich
includes HNF1A and HNF4A. HNF1B+ cells in the pancre-
atic trunk epithelium are multipotent pancreatic progeni-
tors which play a role in endocrine and exocrine develop-
ment (Haumaitre et al., 2005). Although MODY5 was
discovered in 1997, to date the effects of an autosomal
dominant mutation inHN1B on human pancreas develop-
ment and the molecular mechanisms underlying pancre-Stematic hypoplasia remain not fully understood. MODY5
phenotype in humans cannot be phenocopied byHnf1b+/
mice since they do not develop diabetes (Haumaitre et al.,
2005), highlighting the need for a suitable humanmodel to
study the perturbations in pancreas development (Teo
et al., 2013a).
Human-induced pluripotent stem cell (hiPSC)-derived
pancreatic cells now provide an excellent opportunity to
study this monogenic diabetes phenotype. In this study,
we established a well-controlled MODY5-hiPSC pancreatic
differentiation model to elucidate the molecular mecha-
nisms underlying MODY5 pancreatic hypoplasia. We
differentiated four control and six mutant hiPSC lines,
and observed that mutantHNF1BS148L/+ elicits a compensa-
tory increase in definitive endoderm (DE) and pancreatic
transcription factor gene expression. Mutant HNF1BS148L
directly accounted for an increased PDX1 gene expression.
These pancreatic transcription factor network perturba-
tions could possibly explain the occurrence of maturity-
onset diabetes rather than neonatal diabetes despite
pancreatic hypoplasia. Importantly, pancreatic PAX6 gene
expression, known to be important for pancreatic b-cell
function,was distinctly down-regulated inMODY5pancre-
atic progenitors, which in part explains the early-onset dia-
betes and pancreatic hypoplasia in MODY5 patients.Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authors 357
RESULTS
Establishment of a Human Stem Cell Model for
MODY5
We recently reported the derivation of several hiPSC lines
fromaMODY5family (Haldorsenetal., 2008) for invitrodis-
ease modeling of monogenic diabetes (Teo et al., 2013b).
Our experimental design included a ‘‘node’’ comprising a
healthy family member (N805-6) and two members of the
family with an autosomal dominant (S148L) mutation in
the HNF1B gene, of which one of them has developed
diabetes (N805-2) whereas the other has not (N805-1)
(Figure 1A). Three independent hiPSC lines from each
subject were established (iN805-6A/B/C, iN805-1A/B/C,
and iN805-2A/B/C) and verified for the absence or presence
of the S148L (C443T in exon2)mutation in theHNF1B gene
(Figures 1B and S1A).
We then set out to establish a human pancreatic differen-
tiation protocol for disease modeling of MODY5 in vitro
(Figure 1C) based on a chemically defined medium (no
serum) (Teo et al., 2014), which is a modified version of
our recently reported protocol (Teo et al., 2012, 2015).
Careful time-course analyses of differentiated control
hiPSCs (derived from AG16102) (Teo et al., 2013b) indi-
cated that pluripotency factors OCT4 and NANOG
plummet by day 3, and that hiPSCs transit through
EOMES+ MIXL1+ mesendoderm before differentiating
into DE marked by CXCR4, SOX17, GATA4, and GATA6
(Figure 1D).
Further differentiation toward foregut endoderm and
pancreatic progenitors by day 17 revealed an up-regula-
tion of numerous key pancreatic progenitor markers
such as ISL1, HLXB9, HNF1B, PAX6, SOX9, PDX1,
PTF1A, RFX6, NEUROD1, HNF6, DLK1, SOX4, and
MAFB, indicating that our pancreatic differentiation pro-
tocol is suitable for studying the impact of HNF1B S148L/+
mutation on early pancreatic development and its tran-
scriptional network (Figures 1E and S1B). Immunostain-
ing on day 12 and fluorescence-activated cell sorting
(FACS) analyses on day 17 further confirmed the protein
expression of key pancreatic developmental genes (Fig-
ures S1C and S1D). Since HNF1B transcripts exhibit
peak expression between days 7 and 10, we performed
genome-wide microarray analyses on day-10 differenti-
ated control hiPSCs, and confirmed the up-regulation of
pancreas-related genes such as PDX1, HNF1B, ISL1,
RFX6, PAX6, GATA4, GATA6, SOX9, and PTF1A, and a
reciprocal down-regulation of numerous pluripotency-
related genes (Figures 1F and Table S1). Gene ontology
(GO) analyses on up- and down-regulated genes (fold
change >2) indicated general changes in developmental
processes and possibly a down-regulation of vascular
development (Figure S2A).358 Stem Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The AuthoMODY5-hiPSC-Derived Pancreatic Progenitors
Exhibit a Compensatory Increase inDE and Pancreatic
Markers but Down-Regulation of PAX6 Gene
Expression
We first differentiated the MODY5-hiPSCs into DE
(day 3), gut endoderm (days 5–7), and early foregut pro-
genitors (day 10) (Figure 2). Hnf1b gene is expressed as
early as embryonic day 8.75 (E8.75) in the mouse primi-
tive gut/foregut (Ott et al., 1991), corresponding to days
3–7 of the hiPSC in vitro differentiation. Interestingly, we
observed an early compensatory increase in DE markers
CXCR4, SOX17, FOXA2, GATA4, and GATA6 on day 5
and beyond (Figure 2) in the mutant hiPSCs, just when
HNF1B gene is beginning to be expressed (Figure 1E;
days 3–5). This suggests that the early (low) expression
of mutant HNF1B S148L/+ during gut endoderm develop-
ment is already causing an early compensatory increase
in DE and gut endoderm markers.
Given the phenotypic similarities in pancreatic agen-
esis/hypoplasia caused by HNF1B, PDX1, PTF1A, GATA4,
and GATA6 mutations, we hypothesized that the dorsal
pancreatic agenesis in MODY5 (HNF1B S148L/+) (Haldorsen
et al., 2008) could be directly linked to the down-regula-
tion of downstream pancreatic genes GATA4, GATA6,
PDX1, and PTF1A. Surprisingly, time-course transcrip-
tional analyses of MODY5-hiPSC-derived pancreatic pro-
genitors indicate higher gene expression of HNF1B,
PDX1, GATA4, and GATA6 in mutant hiPSCs (iN805-1A/
B/C and iN805-2A/B/C; three independent lines; each
in biological triplicate) compared with two control
hiPSCs (non-family-related control iAG16102 and family
control iN805-6A/B; two independent lines; each in bio-
logical triplicate) (Figure 3A). These findings were also
substantiated by immunostaining of HNF1B and PDX1
on day 12 (Figure 3B; representative of two to three hiPSC
lines) and FACS analyses of SOX9 and PDX1 on day 17
(Figure 3C; two to three hiPSC lines per subject were
pooled together) in MODY5-hiPSC-derived pancreatic
progenitors.
Subsequently, to address the hypothesis that mutant
HNF1B S148L/+ results in its decreased expression and thus
leads to pancreatic hypoplasia and MODY, we analyzed
the transcriptional profile to potentially identify a gene(s)
which is down-regulated in the mutant hiPSC-derived
pancreatic progenitors. Contrary to expectations, we
found a compensatory increase in FOXA2, ISL1, HLXB9,
and RFX6 (Figures S2B and S2C), suggesting that this set
of genes (including HNF1B, PDX1, GATA4, and GATA6)
play an important role in alleviating the negative effects
of mutant HNF1BS148L/+ so as to delay the overall impact
of pancreatic hypoplasia and/or mutant HNF1BS148L/+ on
diabetes onset. Surprisingly, PAX6 was the singular gene
among the many examined to exhibit down-regulationrs
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Figure 1. Establishment of a Human
Stem Cell Model for MODY5
(A) N805 family node pedigree for MODY5
family. Square denotes male, circles denote
females, solid symbol denotes diabetes, NN
denotes no mutation, and NM denotes mu-
tation. N805-6 is a family control, N805-1
has HNF1BS148L/+ phenotype but no diabetes,
whereas N805-2 has HNF1BS148L/+ phenotype
and is diabetic.
(B) S148L (C443T in exon 2) mutation (or
lack thereof) in HNF1B has been verified in
iN805 hiPSCs at least three times.
(C–E) Schematic representation of a human
pancreatic differentiation protocol for dis-
ease modeling of MODY5 in vitro. (C)
CHIR99021 (CHIR) is a GSK-3 inhibitor
whereas LY294002 (LY) is a PI3K inhibitor.
Expression of (D) pluripotency (OCT4 and
NANOG), mesendoderm (EOMES and MIXL1),
definitive endoderm (CXCR4, SOX17, GATA4,
and GATA6) and (E) foregut endoderm (ISL1,
HLXB9, HNF1B, PAX6, SOX9, PDX1, PTF1A, and
RFX6) markers in control hiPSCs differenti-
ated for 17 days. All error bars indicate SD of
three biological replicates in an independent
experiment.
(F) Gene-expression heatmap of representa-
tive pluripotency, mesendoderm, definitive
endoderm, and pancreas-related genes in
undifferentiated (first two columns) and day-
10 differentiated (last two columns) control
hiPSCs (up-regulation in red, down-regula-
tion in blue). The colors in the heatmap de-
pict gene expression in units of SD from the
mean across all samples. Asterisks indicate
genes for which mutations are known to
result in pancreatic hypoplasia/agenesis.
See also Figures S1 and S2.in mutant hiPSC-derived pancreatic progenitors (Fig-
ure 3A). Following this candidate gene approach, we per-
formed microarray analyses for cells obtained from days
0, 12, and 17 (Figure S3A and Table S2). Reassuringly, our
genome-wide analyses indicated that our candidate gene
approach has captured all the key changes in pancreatic
genes: increase in PDX1, ISL1, HNF1B, TCF2, RFX6,
FOXA2, GATA4, GATA6, and HLXB9 (MNX1) expression
in the mutant hiPSC-derived pancreatic progenitors (Fig-
ure S3A). In addition, PAX6 was also the most relevant
pancreatic gene (expressed in our differentiation) to be
down-regulated in the mutant hiPSC-derived pancreatic
progenitors (Figure S3A). Further GO analyses on the up-
and down-regulated genes (fold change >2) on days 12
and 17 mostly reflected changes in developmental pro-
cesses (Figures S3B and S3C). Uniquely, neural develop-Stemment appeared to be more down-regulated in MODY5
pancreatic progenitors on day 17 (Figure S3C).
We then performed chromatin immunoprecipitation
(ChIP) analyses and confirmed that HNF1B binds onto
the genomic loci of HLXB9 and HNF1B (Figure S3D), sug-
gesting that these two genes could be the earliest media-
tors of pancreatic transcription factor network control.
To evaluate whether the HNF1B mutation affected
pancreatic progenitor cell growth, we performed a cell
counting assay and, interestingly, observed that there is
a huge retardation of cell growth from day 12 onward,
when the mutant HNF1B protein exhibits peak expres-
sion (Figure S3E). This strongly suggests that the mutant
HNF1B protein affects pancreatic cell growth, thereby ac-
counting for the pancreatic hypoplasia phenotype in
MODY5.Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authors 359
Figure 2. Transcriptional Perturbations
in MODY5-hiPSC-Derived Early Pancreatic
Progenitors
Gene expression of CXCR4, SOX17, FOXA2,
GATA4, GATA6, and HNF1B in a non-family
control and in iN805 family hiPSCs differ-
entiated for 0, 5, 7 and 10 days. Data are
representative of at least two independent
hiPSC lines per subject. Replicate experi-
ments are presented. The experiments were
replicated at least twice. All error bars
indicate SD of three biological replicates
in an independent experiment. See also
Figures S2 and S3.Wild-Type HNF1B Suppresses, While Mutant HNF1B
Increases, PDX1 Gene Expression
The compensatory increase in bothHNF1B and PDX1 gene
expression in themutant hiPSC-derived pancreatic progen-
itors prompted us to further investigate this molecular
relationship. FACS analyses performed on day-12 differen-
tiated control hiPSCs confirmed that 36.2% are PDX1+
(Figure 4A) whereas 91.4% are HNF1B+ (Figure 5A), corrob-
orating their transcriptional profile (Figure 1E). We first
performed luciferase assays to study the transcriptional
regulation of cardinal pancreatic gene PDX1 (Stoffers
et al., 1997) by HNF1B. Overexpression of HNF1B from
days 10–12 in differentiated control hiPSCs surprisingly
suppressed PDX1 transcriptional activity, in both the
7 kb full-length PDX1 promoter construct and a construct
containing areas I–III of PDX1 promoter (2.4 kb) known
to be the principal control region of PDX1 gene expression
(Gerrish et al., 2000) (Figure 4B). This indicates a repressive
pattern of HNF1B whereby HNF1B gene expression is
decreasing when PDX1 is beginning to be expressed from
days 10–12 (Figure 1E).
HNF1B protein functions either as a homodimer or a het-
erodimer with the structurally related HNF1A (Mendel
et al., 1991; Rey-Campos et al., 1991). We thus overex-
pressed both HNF1B and HNF1A from days 10–12 in differ-
entiated control hiPSCs, only to discover that HNF1A does
not have any transcriptional regulatory effect on PDX1, at
least during this early pancreatic progenitor stage when
PDX1 is beginning to be expressed (Figure 4C). This is
consistent with the observation that HNF1A is expressed360 Stem Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authovery late during pancreatic differentiation (Figure S1D).
Thus, the suppressive effect of HNF1B on PDX1 transcrip-
tional activity is likely due to homodimers in action.
Very little is known about the target genes of HNF1B in a
developing pancreas. HNF4A is one potential candidate
(Thomas et al., 2001). HNF1 binding sites have been found
to be present in pancreas-/islet-specific P2 (Thomas et al.,
2001) and P1 promoters (Taraviras et al., 1994) of the
Hnf4a gene (Eeckhoute et al., 2003). Thus, we cloned
both P1 and P2 promoters of HNF4A, and performed
similar luciferase assays. Dismally, HNF1B overexpression
did not have any effect on P1 promoter and only a very
marginal effect on P2 promoter activity in our stem cell
model on day 12 (Figure S4A), suggesting that the regula-
tion of HNF4A by HNF1B (or HNF1A) is likely apparent
only at later stages of pancreatic development.
To delineate whether the wild-type HNF1B or mutant
HNF1BS148L allele is responsible for the compensatory in-
crease in pancreatic gene expression (Figure 3A), we next
overexpressed wild-type HNF1B or mutant HNF1BS148L
from days 7–10 in differentiated control hiPSCs. Interest-
ingly, overexpression of mutant HNF1BS148L resulted in an
increase in PDX1 gene expression but was insufficient to
up-regulate other pancreatic transcription factors such as
GATA4, GATA6, or SOX9 (Figures 4D and S4B). On the con-
trary, overexpression ofwild-typeHNF1B fromdays 7–10did
not alter the expression level of PDX1 or other genes we
investigated, including GATA4, GATA6, and SOX9 (Figures
4E and S4C). ChIP analyses performed on HNF1B also did
not reveal binding on PDX1 genomic loci (Cebola et al.,rs
AB C
Figure 3. Transcriptional Perturbations
in MODY5-hiPSC-Derived Pancreatic
Progenitors
(A) Gene expression of HNF1B, PAX6, PDX1,
PTF1A, GATA4, and GATA6 in a non-family
control and in iN805 family hiPSCs differ-
entiated for 0, 12, 14, and 17 days. Data are
representative of at least two independent
hiPSC lines per subject. Replicate experi-
ments are presented. The experiments were
replicated at least twice. All error bars
indicate SD of three biological replicates in
an independent experiment.
(B) Immunostaining for HNF1B and PDX1 on
iN805 hiPSCs differentiated for 12 days.
Data are representative of at least two in-
dependent hiPSC lines per subject. The
experiment was replicated at least twice.
Scale bar, 200 mm.
(C) The percentage of PDX1+ and SOX9+ cells
after differentiation of iN805 hiPSCs (two to
three hiPSC lines per subject were pooled
together) for 17 days.
See also Figures S2 and S3.2015 and data not shown). Last but not least, qPCR and
western blot analyses confirmed that the HNF1B and
HNF1A genes/proteins were overexpressed successfully (Fig-
ures S4D and S4E). Together, these data indicate thatmutant
HNF1BS148L (and not HNF1B or HNF1A) gene expression is
responsible for the compensatory increase in PDX1 gene
expression inmutant hiPSC-derived pancreatic progenitors.
The molecular mediator(s) of increased GATA4 and GATA6
gene expression in mutant hiPSC-derived pancreatic pro-
genitors is unclear and requires further investigation.
HNF1B Is Not Directly Involved in Gene Regulation of
PAX6
Pax6 is known to be expressed during early pancreatic
development (E9–9.5) in cells committed exclusively to
the endocrine cell fate (Ashery-Padan et al., 2004; SanderStemet al., 1997). Among the transcription factors we analyzed,
only PAX6 transcripts were clearly down-regulated (Fig-
ure 3A). Since PAX6 exhibits a similar (but right-shifted)
gene-expression profile to that of HNF1B, we sought to
investigate whether HNF1B or HNF1BS148L is involved in
the regulation of PAX6 gene expression. FACS analyses on
day-12 differentiated control hiPSCs (PAX6 peak transcript
expression) (Figure 1E), indicated that 27.2% are PAX6+, of
which 22.0% are also HNF1B+ (Figure 5A). This percentage
of PAX6+ cells is consistent with the report that PAX6
protein is detected only in a small subset of cells in the
pancreatic endoderm at E9–9.5 (Sander et al., 1997). Lucif-
erase assays performed on day-10 differentiated control
hiPSCs indicated that PAX6 promoter is active (Figure 5B).
However, overexpression of HNF1B and/or HNF1A had no
impact, whereas overexpression of mutant HNF1BS148LCell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authors 361
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Figure 4. Mutant HNF1B Is Responsible
for the Increase in PDX1 Gene Expression
(A) The percentage of PDX1+ cells after
differentiation of hiPSCs for 12 days.
(B and C) Luciferase assay showing the ef-
fect of (B) HNF1B and/or (C) HNF1A over-
expression on PDX1 transcriptional activity
in hiPSCs differentiated for 12 days.
(D and E) Expression of pancreas-related
(HNF1B, mutant HNF1B S148L/+, PDX1, GATA4,
and GATA6) markers in hiPSCs differentiated
for 10 days and overexpressing increasing
amounts of (D) mutant HNF1BS148L or (E)
HNF1B from days 7–10. The replicate exper-
iment for mutant HNF1BS148L is presented.
The experiments were replicated at least
twice. All error bars indicate SD of three
biological replicates in an independent
experiment. See also Figure S4.only resulted in a marginal suppression of PAX6 promoter
activity (Figure 5C). Overexpression of wild-type HNF1B
from days 7–10 in differentiated control hiPSCs (Figure 4E)
did not alter PAX6 gene-expression levels (Figure 5D). Over-
expression ofmutantHNF1BS148L alone (Figure 4D)was not
sufficient to suppress PAX6 gene-expression levels (Fig-
ure 5E). Furthermore, HNF1B was not found to bind onto
the PAX6 promoter region (Cebola et al., 2015 and data
not shown). This indicates that the decrease in PAX6
gene expression is an indirect effect of the mutant
HNF1BS148L/+ and is possibly a result of the altered pancre-
atic transcription factor network.
The loss of Pax6 expression early on during pancreatic
development reduces pancreatic insulin content (Ashery-
Padan et al., 2004; Sander et al., 1997) and affects postnatal362 Stem Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authopancreatic b-cell function, which results in early-onset
diabetes (Ashery-Padan et al., 2004). In this study, we
found that PAX6 gene expression is decreased in mutant
(HNF1BS148L/+) hiPSC-derived pancreatic progenitors. To
translate our findings to the MODY5 patients, we tracked
the clinical phenotype of the N805 patients over time.
N805-2 (HNF1BS148L/+) exhibited high fasting glucose
levels (16.3 mmol/l) and required insulin (58–68 units/
24 hr), whereas N805-1 (HNF1BS148L/+), who was not
diabetic, presented with elevated fasting glucose levels
(normal range: 4.0–6.0 mmol/l) and elevated 2-hr glucose
levels after a standard oral glucose challenge (75 g)
(impaired glucose tolerance range: 7.8–11.1 mmol/l) after
the age of 8 years (Figure 5F). N805-2 presented low fasting
insulin (2.4 mIE/l) whereas N805-1 exhibited a transitionrs
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Figure 5. HNF1B Is Not Directly Involved
in Gene Regulation of PAX6
(A) The percentage of HNF1B+ and PAX6+
cells after differentiation of hiPSCs for
12 days.
(B and C) Luciferase assay showing (B) basal
PAX6 promoter activity and (C) the effect of
HNF1B and/or HNF1A overexpression on
PAX6 promoter activity in hiPSCs differen-
tiated for 10 days.
(D and E) Expression of PAX6 in hiPSCs
differentiated for 10 days and over-
expressing increasing amounts of (D)
HNF1B or (E) mutant HNF1B S148L from days
7–10. The experiments in (B) to (E) were
replicated at least twice. All error bars
indicate SD of three biological replicates in
an independent experiment. *p < 0.05 by
two-sided Student’s t test on three inde-
pendent experiments.
(F) Clinical characteristics of MODY5 pa-
tients including HbA1c (%), blood glucose
(glu), insulin (INS), C-peptide (C-pep), and
plasma glucagon (P-GCG) concentrations.
(G) Model depicting the impact of mutant
HNF1BS148L/+ on early human pancreas
development. Mutant HNF1BS148L/+ evokes
an early increase in definitive endoderm
genes followed by a subsequent increase in
pancreas-related foregut endoderm genes.
Thus, although MODY5 patients typically
develop pancreatic hypoplasia there is a
low occurrence of neonatal diabetes. The
decrease in early PAX6 gene expression in
pancreatic progenitors may partly account
for the subsequent b-cell dysfunction in
MODY5 patients.from normal to subnormal levels of fasting insulin, at
5.4mIE/l (normal range: 6.0–27.0mIE/l) (Figure 5F). As dia-
betes develops, plasma glucagon levels usually rise due to
impaired a-cell glucose-sensing function and lack of appro-
priate suppression (Dunning et al., 2005). This scenario fits
with the substantially elevated plasma glucagon levels
(72.2 pmol/l) in the diabetic individual N805-2 and the
moderately elevated plasma glucagon levels in the pre-
diabetic individual N805-1 (46.9 pmol/l; normal range:
14.3–43 pmol/l) (Figure 5F).DISCUSSION
We have successfully established a human stem cell model
to study the molecular mechanisms underlying MODY5.StemOur experimental design, which includes a non-family
control hiPSC line and three independent hiPSC lines
from each of the three subjects in a MODY5 family, is a
well-controlled experimental ‘‘node’’ which minimizes po-
tential genetic background influence and line-to-line varia-
tion in hiPSC differentiation. While we observe HNF1B
gene expression in the family control data to resemble
that in the MODY5-hiPSC-derived pancreatic progenitors
on rare occasions (Figure 2), suggesting initial genetic back-
ground effects (difference between control lines becomes
attenuated later), the use of non-family control samples
provides confidence in the overall distinct phenotypes we
observed in our in vitro stem cell model. In addition,
more than 90% of day-12 differentiated cells are HNF1B+,
making our pancreatic differentiation protocol well suited
for studying MODY5.Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Authors 363
HNF1Bhas been reported to be a transcriptional activator
(Rey-Campos et al., 1991), but any positive regulation of
PDX1 gene expression by HNF1A and/or HNF1B could be
specific to pancreatic b cells (Ben-Shushan et al., 2001)
and not pancreatic progenitors, implying that HNF1B
and/or HNF1A switch their binding partners during
pancreatic development to regulate specificity in gene
regulation.
We observed that mutantHNF1BS148L (and notHNF1B or
HNF1A) gene expression is responsible for the compensa-
tory increase in PDX1 gene expression in mutant hiPSC-
derived pancreatic progenitors. This could, in part, be
acting to counter the increased transcriptional repression
by wild-type HNF1B (Figures 3B and 3C), although
increasing HNF1B gene expression for 3 days from days 7
to 10 appears to be insufficient to significantly suppress
PDX1 gene expression (Figure 4E). This gene regulation is
likely to be indirect, since we did not find HNF1B protein
to be bound onto the genomic loci of PDX1 (Cebola
et al., 2015). It is interesting to note that b-cell-specific
knockout of Hnf1b similarly results in an increase in Pdx1
gene expression (Wang et al., 2004), indicating that pertur-
bations in HNF1B gene expression, either early during
pancreatic development or in mature b cells, both prompt
compensatory PDX1 gene expression.
The presence of a wild-type HNF1B allele and the combi-
natorial effects of wild-type-mutant HNF1B dimers in
MODY5 (HNF1BS148L/+) patients partly explains the
compensatory up-regulation of numerous pancreatic tran-
scription factors. The lack of down-regulation of critical
pancreatic genes PDX1, PTF1A,GATA4, andGATA6 implies
that the mechanism underlying dorsal pancreatic agenesis
in MODY5 is independent of these genes, which are also
known to result in pancreatic agenesis/hypoplasia when
mutated (D’Amato et al., 2010; Lango Allen et al., 2012;
Sellick et al., 2004; Stoffers et al., 1997). This compensation
in pancreatic transcriptional network due to an HNF1B
autosomal dominant mutation may also account for the
diabetes onset relatively later in life seen in MODY5
compared with the early onset observed in genetic forms
of neonatal diabetes (Teo et al., 2013a) (Figure 5G). In
this context, it is interesting that the MODY5 subjects
with dorsal pancreatic agenesis also exhibit compensatory
increase in physiological acinar function with hypersecre-
tion from the remaining ventral portions of the pancreas
(Tjora et al., 2013).
Hnf1b/ mice with pancreatic agenesis exhibit loss of
numerous pancreatic genes, including Pax6 expression
(Haumaitre et al., 2005). Pax6-deficient pancreatic progeni-
tors that are unable to mature and reach terminal differenti-
ation later in life cannot be rescued by postnatal neogenesis
(Ashery-Padanetal.,2004).Thus, the reductioninpancreatic
endocrine cell number in Pax6/ embryos (Sander et al.,364 Stem Cell Reports j Vol. 6 j 357–367 j March 8, 2016 j ª2016 The Autho1997) and altered acinar structure (Hart et al., 2013) could
partly account for the pancreatic hypoplasia phenotype in
MODY5 patients. Given that PAX6 directly regulates genes
that regulate b-cell function (Ashery-Padan et al., 2004;
Wen et al., 2009), we speculate that the loss of PAX6 gene
expression early on in the MODY5 patients also partly ac-
counts for the b and a islet cell dysfunction, and contributes
to their diabetic phenotype (Figure 5G). This concept is
concordant with the observations that patients with PAX6
heterozygous mutations also develop glucose intolerance
(Wen et al., 2009; Yasuda et al., 2002). It is interesting to
note that administration of exendin-4, a glucagon-like pep-
tide 1 receptor (GLP-1R) agonist, to Pax6+/ mice can rescue
the metabolic abnormalities observed, either via increased
insulin secretion or b-cell regeneration (Ding et al., 2009),
suggesting a potential for treatment for patients lacking
pancreatic PAX6 gene expression, and the MODY5 patients
in this study.
Collectively, we have evaluated the impact of a MODY5-
causing point mutation (S148L) in the HNF1B gene on hu-
man pancreas development using a unique human stem
cell model. We report molecular phenotypes (up- and
down-regulation of pancreatic genes) when HNF1B is
increasingly expressed from days 7 to 10, and observed
that these phenotypes extend beyond the expression win-
dow of HNF1B. These data provide insights into the long-
term impact of the MODY5 mutation on the pancreatic
transcriptional network and the subsequent development
of human pancreatic progenitors into mature functional
endocrine cells. This is in agreement with Haumaitre
et al. (2006), who indicated that MODY5 is certainly due
to defective morphogenesis of the pancreas. Future efforts
to further differentiate these hiPSCs into pancreatic b cells
will reveal the impact of transcriptional perturbations on
b-cell formation and function.EXPERIMENTAL PROCEDURES
Cell Culture
Informed consent was obtained fromMODY5 patients. This study
was reviewed and approved by the Institutional Review Boards at
Haukeland University Hospital and Joslin Diabetes Center, and
in accordance with the principles set out in the WMA Declaration
of Helsinki and theDepartment of Health andHuman Services Bel-
mont Report. hiPSCs used were tested mycoplasma negative and
were cultured as described previously (Teo et al., 2013b, 2014).
hiPSCswere differentiated into pancreatic progenitors as described
previously (Teo et al., 2014). In general, 2–3 independent hiPSC
lines per subject were used, and biological triplicates were used
for each hiPSC line.
Sequencing of MODY5-hiPSCs
The method for sequencing has been described previously (Teo
et al., 2013b).rs
qRT-PCR, Immunostaining, FACS, Western Blot, and
ChIP Analyses
Methods for qRT-PCR, immunostaining, FACS, western blot (Teo
et al., 2014), and ChIP analyses (Cebola et al., 2015; Teo et al.,
2011, 2015) have been described previously. p < 0.05 indicates sta-
tistical significance by Student’s t test (two-sided; equal variance).
In general, qRT-PCR and immunostaining data of MODY5-
hiPSC-derived cells are representative of one non-family control
hiPSC line (iAG16102), two family control hiPSC lines (iN805-
6A/C), and three lines each for the two MODY5 patients (iN805-
1A/B/C and iN805-2A/B/C). All error bars indicate SD of three bio-
logical replicates. Two to three hiPSC lines per subject were pooled
together before being set up in triplicate for FACS analyses. Primers
and antibodies used are provided in Table S3.Microarray
Microarray was performed by the Molecular Genetics Core Facility
at Children’s Hospital, Boston. Two biological replicates for undif-
ferentiated and day-10 differentiated control hiPSCs were
analyzed. One sample from iAG16102, iN805-6, iN805-1, and
iN805-2 each was used for day-0, -12 and -17 analyses.Gene Ontology Overrepresentation Analysis
The overrepresentation of GO biological process categories was as-
sessed using DAVID.Overexpression Studies
HNF1B gene was amplified from cDNA obtained from differenti-
ated hPSCs using PfuUltra II Fusion HS DNA Polymerase with a
melting temperature (Tm) of 50C and extension at 72C for
2min.HNF1B cDNAwas then subcloned into pCDH-FlagV5 vector
using EcoRI and XhoI RE sites to obtain pCDH-hHNF1B. HNF1B
cDNA was also subcloned into PCR-Blunt II-TOPO vector, and
hHNF1BC443TF and hHNF1BC443TR primers were used to
amplify HNF1BS148L using PfuUltra II Fusion HS DNA Polymerase
with an extension at 72C for 5 min. HNF1BS148L cDNA was then
subcloned into pCDH-FlagV5 vector using EcoRI and XhoI RE sites
to obtain pCDH-hHNF1BS148L. pcDNA3.1-hHNF1Awas a gift from
Y.-I. Chi. Primers used are provided in Table S3. Day-6 differenti-
ated control hiPSCs were split and replated onto 12-well plates.
These cells were transducedwith lentiviruses (multiplicity of infec-
tion 10, 20, 30 or 50, 100, 200) containing pCDH-GFP, pCDH-
HNF1B, or pCDH-HNF1BS148L on day 7, washed with PBS on day
8, and harvested on day 10.Luciferase Assays
hPDX1 promoter (7 kb) was cloned into pGL4.10 using NheI and
XhoI RE sites. hPDX1 promoter/enhancer (areas I–III) was cloned
into pGL4.23 usingXhoI andBglII RE sites. hHNF4A P1 and P2 pro-
moters were cloned into pGL4.10 using KpnI and XhoI RE sites.
hPAX6 promoter (346 bp) containing HNF1B and HNF1A binding
sites was a gift from Y.-H. Zhou. Primers used are provided in Table
S3. Day-9 differentiated control hiPSCs were split and replated
onto 12-well plates. These cells were transfected with hPDX1 pro-
moter, hHNF4A P1 or P2 promoter in the absence and presence of
pCDH-HNF1B, and/or pcDNA3.1-hHNF1A on day 10 and har-Stemvested on day 12. Day-6 differentiated control hiPSCs were split
and replated onto 12-well plates. These cells were transfected
with hPAX6 promoter in the absence and presence of pCDH-GFP,
pCDH-HNF1B, pCDH-HNF1BS148L, and/or pcDNA3.1-hHNF1A on
day 7 and harvested on day 10. The method for luciferase assay
has been described previously (Teo et al., 2011).
Hormone Assays
Glucagon was assessed with a radioimmunoassay from Millipore.
This assay reports a precision (coefficient of variation) for high
levels (72.4 pmol/l) of 10.1%, for intermediate levels (52.2 pmol/l)
of 12.6%, and for low levels (28.8 pmol/l) of 9.2%. Prior to analysis,
we collected blood samples in plasma tubes containing 250 kIU
Trasvlol (Aprotinin) per ml of whole blood. This resulted in a final
concentration of approximately 500 kIU Trasvlol per ml of serum
or plasma, and the aliquot was frozen at 70C.
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Microarray data have been uploaded to GEO with accession
number GEO: GSE74885.
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